By the end of 2018, Tchaikapharma expects to be issued with Marketing Authorizations for three new prescription drugs, which will enrich the portfolio and the well-developed therapeutic baskets of the company with the following medications and indications:
Chlorthidon (chlorthalidone) – for the treatment of arterial hypertension, essential or renovascular, or isolated systolic hypertension.
PlaquEx Combi (clopidogrel/acetylsalicylic acid) – for the secondary prevention of acute cardiovascular events.
Methylprednisolone-Tchaikapharma (methylprednisolone) – for the treatment of endocrine, rheumatic, collagenosis and immune-complex, skin, eye, gastrointestinal, respiratory, hematological, oncology and edema diseases, as well as allergic conditions.
Tchaikapharma International Press Center
Tchaikapharma completed the bioequivalence clinical trials of 4 new dual-component pharmaceutical products for the treatment of arterial hypertension and other cardiovascular diseases – with sucsess. The new drug fixed-dosage combinations with angiotensin receptor blockers and thiazide or thiazide-similar diuretics represent innovative solutions for an advanced medical care.
The researched and other already registered new combined pharmaceutical products are innovative scientific solutions developed by Tchaikapharma and are extensively prescribed by doctors and are met with a wide satisfaction by patients – in Bulgaria and a number of pharmaceutical markets in the EU.
On 20 August 2018, the Food and Drug Administration of the USA made a proposal for simplification of the registration procedure for exactly this kind of pharmaceutical combinations and the Administration described them as “complex” and accepted their innovative combined effect and high efficacy, which cannot be found in the already known mono-component generic medications.
Tchaikapharma’s laboratories are completing the development, and more importantly, are about to finish – within the next 18 months – the clinical trials of the three-component pharmaceutical products for the treatment of cardiovascular disease and diabetes.
Cardiovascular diseases and diabetes are the chronicle conditions with the highest morbidity and longest duration in the EU countries, which lead to acute complications such as myocardial infarction, stroke and other severe life-threatening events.
Tchaikapharma International Press Center
Pizona Combi contains pioglitazone and metformin that controls blood sugar levels.
It helps the body to utilize better produced by body insulin when metformin alone is insufficient.
The medicinal product is subject to medical prescription.
For more details, please check section Products
ATC код: A10B 02
The 33rd National Meeting of the Association of Medical Students in Bulgaria was held in Pleven from 16 to 18 March with the support of Tchaikapharma.
A specially designed booth will welcome the participants in the eighth scientific conference of the Bulgarian Cardiac and Vascular Association under the auspices of the Rector of the Medical University of Pleven. The conference entitled “Contemporary Accents in Cardiac and Vascular Pathology” starts tomorrow, 30 March 2018, and will last for two days.
Tchaikapharma has won award in the category of solution providers during the Pharm Connect congress which is the most notable meeting of leading pharmaceutical and biotechnology companies for Central Eastern Europe and CIS region.
The excellence award was given for the successful incorporation of the latest running and implementation system. This has been a joint project of Tchaikapharma and Softgroup ,the latter creating the software and providing the technical equipment for the system.
The purpose of all that was to build a running system that meets all the requirements of some of the European directives for falsified medicines. This leads to the fact that production capacity will be connected to the European hub for tracking every package that has been produced and sold.
Tchaikapharma is the fastest growing pharmaceutical manufacturer operating in Bulgaria. The company is focused on making available contemporary therapeutic solutions on the local, regional and European market in accordance with GMP. Tchaikapharma has an annual manufacturing capacity of 500 million tablets and 17 million secondary packaging boxes.